SBC Medical Group
SBC
5 hedge funds and large institutions have $1.9M invested in SBC Medical Group in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
1.25% less ownership
Funds ownership: 4.3% → 3.06% (-1.2%)
29% less capital invested
Capital invested by funds: $2.67M → $1.9M (-$770K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$126K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$15.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$526K |
| 2 |
Walleye Trading
New York
|
-$296K |
| 3 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$180K |
SBC Hedge Fund Activity: Q2 2024 in Review
5 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in SBC Medical Group (SBC) for Q2 2024, worth a combined $1.9M — down 29% from $2.67M a quarter earlier.
Fund positioning in SBC was balanced in Q2 2024: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Clear Street, opening a new position worth an estimated $126K. The largest seller was Walleye Capital, cutting an estimated $526K.
- 5 institutional investors held SBC Medical Group (SBC) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $1.9M of SBC Medical Group stock for Q2 2024, down 29% quarter-over-quarter.
- 1 fund opened new SBC Medical Group positions in Q2 2024 and 1 closed out, a net change of 0 holders.
- The largest SBC Medical Group buyer in Q2 2024 was Clear Street, an estimated $126K added.
- The largest SBC Medical Group seller in Q2 2024 was Walleye Capital, an estimated $526K sold.
Based on aggregated 13F filings for Q2 2024.